Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120418 · ClinicalTrials.gov registry record · Phase 1
Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT01120418 is a Phase 1 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 120 participants.
The verdict
NCT01120418, a Phase 1 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect on corneal endothelial cell density changes when ISV-403 is administered for five (5) days compared to no drug treatment, in healthy subjects.
Interventions
- DRUG Besifloxacin Ophthalmic Suspension 0.6%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01120418
The ClinicalTrials.gov registry entry for NCT01120418 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Besifloxacin Ophthalmic Suspension 0.6% is the first listed.
NCT01120418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01120418 about?
NCT01120418 is a clinical study titled "Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days". The objective of this study is to evaluate the effect on corneal endothelial cell density changes when ISV-403 is administered for five (5) days compared to no drug treatment, in healthy subjects.
What is the current status of trial NCT01120418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2007-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT01120418?
The interventions under investigation include: Besifloxacin Ophthalmic Suspension 0.6% (DRUG).
Who is sponsoring clinical trial NCT01120418?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.